Biovica International AB (publ)

Stockholm Stock Exchange BIOVIC-B.ST

Biovica International AB (publ) Operating Income Margin for the year ending April 30, 2024: -1,739.99%

Biovica International AB (publ) Operating Income Margin is -1,739.99% for the year ending April 30, 2024, a 46.69% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Biovica International AB (publ) Operating Income Margin for the year ending April 30, 2023 was -3,264.10%, a -11.06% change year over year.
Biovica International AB (publ) Operating Income Margin for the year ending April 30, 2022 was -2,938.92%, a -51.92% change year over year.
Biovica International AB (publ) Operating Income Margin for the year ending April 30, 2021 was -1,934.57%, a -8.42% change year over year.
Biovica International AB (publ) Operating Income Margin for the year ending April 30, 2020 was -1,784.32%, a -146.89% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Stockholm Stock Exchange: BIOVIC-B.ST

Biovica International AB (publ)

CEO	Mr. Anders Rylander
IPO Date	March 29, 2017
Location	Sweden
Headquarters	Dag HammarskjOelds vAeg 54B
Employees	27
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.

Key trends

Past 5 years